Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Terminated 4Withdrawn 3Recruiting 3Approved for marketing 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 23Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Waldenstrom Macroglobulinemia 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, B-Cell 4Leukemia 3Neoplasms 2Melanoma 2Leukemia, Prolymphocytic 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1Myeloproliferative Disorders 1Lymphoma, AIDS-Related 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Hematologic Diseases 1Graft vs Host Disease 1Glioblastoma 1Disease Progression 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Gemcitabine 6Cisplatin 6Bortezomib 6venetoclax 5elotuzumab 4isatuximab 3blinatumomab 3Vincristine 3Radiotherapy 3Prednisone 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2ixazomib 2dexamethasone 21-phosphate 2cabazitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × ibrutinib × Clear all
NCT03734198 2025-11-26

IDA53

French Innovative Leukemia Organisation

Phase 2 Active not recruiting
29 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡